Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative capecitabine plus SIB-IMRT in locally advanced rectal cancer
ChiCTR-ONC-12002387Phase 2Completed
- Sponsor
- Chinese PLA General Hospital
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer, sponsored by Chinese PLA General Hospital. Primary endpoints: Pathological complete response rate, Tumor down-staging and 1 more. Started Feb 2012; status: completed.
02
Drugs
capecitabine
03
Conditions
rectal cancer
Beyond the preview
Go deeper on ChiCTR-ONC-12002387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONC-12002387.